Maxcyte (MXCT) Cash & Equivalents (2020 - 2026)

Maxcyte (MXCT) has 7 years of Cash & Equivalents data on file, last reported at $14.6 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $14.6 million, down 37.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.6 million (down 37.75% YoY), and the FY2025 annual result was $20.1 million, down 28.04% from the prior year.
• Cash & Equivalents slipped to $14.6 million in Q1 2026 per MXCT's latest filing, from $20.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $239.8 million in Q1 2022 and troughed at $11.1 million in Q4 2022.
• A 5-year average of $47.2 million and a median of $37.0 million in 2024 frame the typical range for Cash & Equivalents.
• On a YoY basis, Cash & Equivalents climbed as much as 320.3% in 2023 and fell as far as 84.22% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $11.1 million in 2022, then surged by 320.3% to $46.5 million in 2023, then sank by 40.04% to $27.9 million in 2024, then slipped by 28.04% to $20.1 million in 2025, then retreated by 27.45% to $14.6 million in 2026.
• Business Quant data shows MXCT's Cash & Equivalents at $14.6 million in Q1 2026, $20.1 million in Q4 2025, and $13.0 million in Q3 2025.